Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Recordati Industria Chimica e Farmaceutica SPA ( (IT:REC) ) has provided an announcement.
Recordati has published the lists of candidates for its new Board of Statutory Auditors ahead of the ordinary and extraordinary shareholders’ meeting scheduled for 29 April 2026. The disclosure fulfils regulatory requirements and signals an orderly governance process at a time when the company continues to expand its global pharmaceutical footprint.
One list was submitted by majority shareholder Rossini S.à r.l., which holds 46.82% of Recordati’s share capital and has also tabled a proposal on auditor remuneration, while a second list comes from a coalition of asset managers and institutional investors representing 0.67017% of capital. The availability of these lists on multiple public platforms enhances transparency for investors and underscores active participation by both controlling and minority shareholders in shaping the group’s oversight structure.
The most recent analyst rating on (IT:REC) stock is a Buy with a EUR56.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
More about Recordati Industria Chimica e Farmaceutica SPA
Recordati Industria Chimica e Farmaceutica is an international pharmaceutical group listed on Borsa Italiana, originating from a family-run pharmacy in Northern Italy in the 1920s. The company develops, produces, markets and licenses active pharmaceutical ingredients and finished drugs for both general and specialist medicine, with a strong focus on rare diseases across about 150 countries in EMEA, the Americas and APAC.
Recordati operates via a fully integrated model spanning clinical development to commercialization, supported by more than 4,580 employees worldwide. Its stated purpose is to expand access to treatments by addressing the needs of patients with common and rare conditions, underlining a mission that frames health as a fundamental right rather than a privilege.
Average Trading Volume: 368,342
Technical Sentiment Signal: Buy
Current Market Cap: €10.14B
Find detailed analytics on REC stock on TipRanks’ Stock Analysis page.